

International AIDS Society iasociety.org





Latest Scientific Updates on HIV &TB co-infections, including TPT

Darma Imran

Cipto Mangunkusumo Hospital - Jakarta Faculty of Medicine University of Indonesia

IAS Educational Fund Workshopo Program Jakarta, 9-10 November 2022




Topic

- 1. Impact of Covid-19 on HIV-TB Death in 2019-2020
- 2. Barriers to healthcare engagement in TB
- 3. TB Screening
- 4. TB diagnostic
- 5. TB Preventive Therapy (TPT)
- 6. Treatment of HIV-TB and TB Meningitis





Impact of Covid-19 on HIV-TB Death in 2019-2020




• 2006 – 2019

- 68% decline in TB deaths among people living with HIV
- 2021 (Global Tuberculosis Report):
 - TB deaths among PLHIV increased for the first time in 13 years
 - from 209.000 in 2019 to → 214.000 in 2020





Barriers to healthcare engagement in TB



Patient pathways and delays to diagnosis and treatment of tuberculosis in an urban setting in Indonesia *B.W. Lestari, The Lancet Regional Health 2020*


50% had one month delay in seeking care for their symptoms





Tuberculous meningitis patient pathways and delays to diagnosis in Indonesia: a retrospective cohort analysis 2020

- RSHS (Bandung) & RSCM (Jakarta)
- Median total delay from onset of first symptoms to TBM diagnosis was 66 days (IQR 31-138).
 - Some patients were diagnosed with TBM around two years after onset of symptoms.
- Patients had a median 5 healthcare visits (IQR 3-8), up to a maximum of 24 visits for one patient




Time since start of the first symptom





Screening TB symptoms to initiate TPT

*TPT = TB preventative therapy



WHO 4-syptoms screening:

- 1. Presence of cough
- 2. Fever
- 3. Night sweats
- 4. Weight loss


Positive screening still require confirmatory testing before TPT could be initiated -> barrier to prompt initiation of TPT







C-reactive protein TB screening in HIV



CRP-based screening had higher specificity compared with WHO 4-symptom screening

- WHO 4-symptom screen
 - Sensitivity 82%
 - Specificity 42%
- CRP > 10 mg/L
 - Sensitivity 77%
 - Specificity 74%

Dhana et al. Tuberculosis screening in HIV (meta-analysis). Lancet Infect Dis 2022






TB Preventative Therapy (TPT)

- People living with HIV with latent TB infection are 20 times more likely to develop active TB. Initiation of ART not prevent reactivation of latent TB.
- The Temprano randomized controlled trial(RCT) found that 6 months of TPT reduced TB mortality by 39%.
- \circ WHO Global tuberculosis report 2020: only 21% of eligible PLHIV initiated TPT globally.

<u><u></u>RIAS</u>





One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis Swindells, NEJM 2019

shorter regimens had the highest proportions of treatment completion

Yanes-Lane et al. Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. PLOS Medicine. 2021

IAS Educational Fund Workshopo Program Jaka


Jakarta, 9-10 November 2022



Latent Tuberculosis Infection Treatment Regimens

Treatment regimens for latent TB infection (LTBI) use isoniazid (INH), rifapentine (RPT), or rifampin (RIF). **CDC and** the National Tuberculosis Controllers Association preferentially recommend short-course, rifamycin-based, 3- or 4-month latent **TB** infection treatment regimens over 6- or 9-month isoniazid monotherapy.

Clinicians should choose the appropriate treatment regimen based on drug susceptibility results of the presumed source case (if known), coexisting medical conditions (e.g., HIV*), and potential for drug–drug interactions. https://www.cdc.gov/mmwr/volumes/69/rr/rr6901a1.htm?s_cid=rr6901a1_w



"For persons with HW/NDS, see Guidelines for the Use of Antinetroviral Agents in Adults and Adolescents Living with HIV available at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-ary/367/overview.

†isoniazid is formulated as 100-mg and 300-mg tablets.

†Rifapentine is formulated as 150-mg tablets in blister packs that should be kept sealed until use.

Fintermittent regimens must be provided via directly observed therapy (i.e., a health care worker observes the ingestion of medication).

§Rifampin (rifampicin) is formulated as 150-mg and 300-mg capsules.

The American Academy of Pediatrics acknowledges that some experts use rifampin at 20-30 mg/kg for the daily regimen when prescribing for infants and toddlers (Source: American Academy of Pediatrics.



PUI-PT

Unika Atma Jaya

Indonesia

Coalition

AIDS

Red box : adopted by our current guideline





Status of the available AlereLAM and FujiLAM against Criteria of Rapid TB Diagnostic (WHO-TPP)

	WHO TPP Criteria	AlereLAM	FujiLAM	Xpert MTB/RIF Ultra Xpert MTB/RIF Smear Microscopy
Sensitivity in HIV positive (independent of CD4 count)	> 65% (not specifically defined for HIV-positives in the TPP)	42% [Bjerrum, S-2019]	70.7% [Broger, T-2022]	90% (Xpert MTB/RIF Ultra) [Dorman,S.E-2018] 77% (Xpert MTB/RIF) [Dorman,S.E-2018] 47% (Microscopy)
Specificity	98%	96–98% against CRS [Shah, M-2016]	95.7% against CRS [Broger, T2019]	96% (Xpert MTB/RIF Ultra) [Dorman,S.E-2018] 98% (Xpert MTB/RIF) [Dorman,S.E-2018] 98% (Microscopy)
Time-to-result	< 60 min	25 min	50 min	100 min (Xpert)

Modified from: Bulterys MA et al. Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: J Clin Med. 2019

IAS Educational Fund Workshopo Program

Jakarta, 9-10 November 2022





Treatment of HIV-TB

• Pulmonary TB

 ART should be started within 2 weeks regardless of CD4 cell count following initiation of antituberculosis treatment. [WHO 2021]

• TB Meningitis:

- ART should be delayed at least 4 weeks (and initiated within 8 weeks) after treatment for TB meningitis is initiated.[WHO 2021]
- There is increasing evidence that we are underdosing RIF in many people with TB and that higher RIF doses are safe and well tolerated

Dooley KE. Am J Respir Crit Care Med 2018





Do TB Drugs get to the site of infection? And how do we measure this?

WHO recommends 2HRZE/10HR with R dose of 10-20 mg/kg for TBM

Drug	CSF:serum ratio*		
Isoniazid	0.8-1.0		
Rifampicin	0.04-0.11		
Pyrazinamide	0.79-1.05		
Ethambutol	Negligible (<mic even="" meningitis)<="" td="" with=""></mic>		
Ethionamide	Good		
Fluoroquinolones	0.7-0.8		
Streptomycin	Poor, decreases with restoration of blood-brain barrier on treatment		


Slide from Kelly Dooley, MD, PhD - 3rd Tuberculous Meningitis International Consortium Meeting, Lucknow, India March 1st & 2nd, 2018 Donald (2010) Tuberculosis 90: 279.

IAS Educational Fund Workshopo Program Jakarta, 9-10 November 2022






Right dose of Rifampicin for TBM?



Survival in <u>adults</u> with TBM dramatically increased as oral dose goes from 10 mg/kg (450 mg) to 30 mg/kg (1350 mg)

Svensson et al Union Meeting, the Hague , 2018



To achieve the target exposure associated with reduced mortality in adults (Cmax of about 22), children would need at least 30 mg/kg of oral rifampicin daily


Savic et al CPT 2015 98:622.





Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered with Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals

Cerrone M et al. Clin Infect Dis. 2019









Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial

Griesel R, Hill A et al. Wellcome Open Res. 2021



Virological suppression at week 24 in both arms were acceptable







Efficacy of high-dose RIF against EFV dan DTG?

STUDY PROTOCOL

Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF)

Ruth Nabisere¹, Joseph Musaazi¹, Paolo Denti², Florence Aber¹, Mohammed Lamorde¹, Kelly E. Dooley³, Rob Aarnoutse⁴, Derek J. Sloan⁵ and Christine Sekaggya-Wiltshire^{1*}

Open Access



Ongoing study

International AIDS Society iasociety.org



Conclusions

RIAS

- 1. The increase in TB deaths among people living with HIV is alarming and need urgent action.
- 2. Delays in detection and initiation of tuberculosis treatment can be barriers to effective disease control.
- 3. CRP is an attractive candidate as a triage test for TB-HIV.
- 4. TPT with shorter regimens had the highest proportions of treatment completion.
- 5. Based on current publication available Urine LAM meets WHO high priority TPP requirements.
- 6. There is increasing evidence that we are underdosing RIF in many people with TBM and that higher RIF doses are safe and well tolerated.



International AIDS Society iasociety.org





Thank you

Darma Imran

Cipto Mangunkusumo Hospital - Jakarta Faculty of Medicine University of Indonesia Email: darma_Imran@yahoo.com

IAS Educational Fund Workshopo Program Jakarta, 9-10 November 2022